BRISTOL MYERS SQUIBB CO
For the period ended Sep 30, 2024. Filed Oct 31, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2024 · Filed Oct 31, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Summary of Abbreviated Terms
Bristol-Myers Squibb Company and its consolidated subsidiaries may be referred to as Bristol Myers Squibb, BMS, the Company, we, our or us in this Quarterly Report on Form 10-Q, unless the context otherwise indicates. Throughout this Quarterly Report on Form 10-Q we have used terms which are defined below:
| 2023 Form 10-K | Annual Report on Form 10-K for the fiscal year ended December 31, 2023 | Mirati | Mirati Therapeutics, Inc. |
|---|---|---|---|
| 2024 Senior Unsecured Notes | Aggregate principal amount of $13.0 billion of unsecured senior notes issued by BMS in February 2024 | MPM | malignant pleural mesothelioma |
| aGVHD | acute graft-versus-host disease | MTA | Methylthioadenosine |
| ANDA | Abbreviated New Drug Application | NDA | New Drug Application |
| AstraZeneca | AstraZeneca PLC | Nimbus | Nimbus Therapeutics |
| BCMA | B-cell maturation antigen-directed | NKT | natural killer T |
| BLA | Biologics License Application | NSCLC | non-small cell lung cancer |
| CAR-T | chimeric antigen receptor T-cell | NTRK | Neurotrophic Tropomyosin Receptor Kinase |
| Celgene | Celgene Corporation | NVAF | non-valvular atrial fibrillation |
| CERCLA | U.S. Comprehensive Environmental Response, Compensation and Liability Act | OECD | Organization for Economic Co-operation and Development |
| CGDP | Coverage Gap Discount Program | Ono | Ono Pharmaceutical Co., Ltd |
| CLL | Chronic Lymphocytic Leukemia | Otsuka | Otsuka Pharmaceutical Co., Ltd. |
| CML | chronic myeloid leukemia | PD-1 | programmed cell death protein 1 |
| CRC | colorectal carcinoma | PD-LI | programmed death-ligand 1 |
| CTLA4 | Cytotoxic T-lymphocyte Antigen-4 | PsA | psoriatic arthritis |
| DLBCL | Diffuse Large B-cell Lymphoma | PRMT5 | protein arginine methyltransferase 5 |
| EC | European Commission | Quarterly Report on Form 10-Q | Quarterly Report on Form 10-Q for the quarter ended September 30, 2024 |
| Eisai | Eisai Co., Ltd. | R&D | research and development |
| EPS | earnings per share | RA | rheumatoid arthritis |
| EU | European Union | RayzeBio | RayzeBio, Inc. |
| Exchange Act | the Securities Exchange Act of 1934 | RCC | renal cell carcinoma |
| FASB | Financial Accounting Standards Board | RDFV | readily determinable fair values |
| FDA | U.S. Food and Drug Administration | REMS | risk evaluation and mitigation strategy |
| FL | follicular lymphoma | Sanofi | Sanofi S.A. |
| GAAP | generally accepted accounting principles | SEC | U.S. Securities and Exchange Commission |
| GTN | gross-to-net | SLL | Small Lymphocytic Lymphoma |
| HCC | hepatocellular carcinoma | SPC | Supplementary Protection Certificate |
| HCM | hypertrophic cardiomyopathy | SystImmune | SystImmune, Inc. |
| IPRD | in-process research and development | Takeda | Takeda Pharmaceutical Company Limited |
| IRA | Inflation Reduction Act of 2022 | TCJA | Tax Cuts and Jobs Act |
| IRS | Internal Revenue Service | Turning Point | Turning Point Therapeutics, Inc. |
| JIA | juvenile idiopathic arthritis | UC | ulcerative colitis |
| Karuna | Karuna Therapeutics, Inc. | UK | United Kingdom |
| KRAS | Kirsten rat sarcoma | U.S. | United States |
| LBCL | Large B-cell Lymphoma | USPTO | U.S. Patent and Trademark Office |
| MDS | myelodysplastic syndromes | VAT | value added tax |
| Merck | Merck & Co. | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.